TVTX — Travere Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.81bn
- $2.80bn
- $490.73m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 48.9 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 24.45 | ||
| Price to Tang. Book | 2,924.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -14.11% | ||
| Return on Equity | -57.8% | ||
| Operating Margin | -12.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 131.84 | 109.46 | 145.24 | 233.18 | 490.73 | 692.2 | 921.72 | 19.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +1042.01 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Directors
- Gary Lyons CHM (69)
- Eric Dube PRE (48)
- Laura Clague CFO (62)
- Elizabeth Reed SVP (50)
- William Rote SVP (58)
- Sandra Calvin CAO (56)
- Peter Heerma OTH (50)
- Jula Inrig OTH
- Stephen Aselage DRC (69)
- Roy Baynes IND (66)
- Suzanne Bruhn IND (57)
- Timothy Coughlin IND (54)
- Jeffrey Meckler IND (54)
- John Orwin IND (55)
- Sandra Poole IND (57)
- Ron Squarer IND (54)
- Ruth Williams-brinkley IND
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- February 7th, 2008
- Public Since
- July 23rd, 2003
- No. of Shareholders
- 158
- No. of Employees
- 497
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 92,241,550
- Address
- 3611 Valley Centre Dr, Suite 300, SAN DIEGO, 92130
- Web
- https://travere.com/
- Phone
- +1 7602608600
- Auditors
- Ernst & Young LLP
Upcoming Events for TVTX
Travere Therapeutics Inc Annual Shareholders Meeting
Q2 2026 Travere Therapeutics Inc Earnings Release
Similar to TVTX
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the Travere Therapeutics share price?
As of Today at 23:47 UTC, shares in Travere Therapeutics are trading at $30.44. This share price information is delayed by 15 minutes.
How has the Travere Therapeutics share price performed this year?
Shares in Travere Therapeutics last closed at $30.44 and the price had moved by +69.68% over the past 365 days. In terms of relative price strength the Travere Therapeutics share price has outperformed the S&P500 Index by +30.79% over the past year.
What are the analyst and broker recommendations for Travere Therapeutics?
The overall consensus recommendation for Travere Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Travere Therapeutics dividend yield?
Travere Therapeutics does not currently pay a dividend.
Does Travere Therapeutics pay a dividend?
Travere Therapeutics does not currently pay a dividend.
When does Travere Therapeutics next pay dividends?
Travere Therapeutics does not currently pay a dividend.
How do I buy Travere Therapeutics shares?
To buy shares in Travere Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Travere Therapeutics?
As of the previous close price of $30.44, shares in Travere Therapeutics had a market capitalisation of $2.81bn.
Where are Travere Therapeutics shares listed?
Here are the trading details for Travere Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TVTX
What kind of share is Travere Therapeutics?
Based on an overall assessment of its quality, value and momentum Travere Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Travere Therapeutics share price forecast for 2026?
The analyst consensus target price for shares in Travere Therapeutics is $42.62. That is 40.01% above the last closing price of $30.44.
Analysts covering Travere Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $0.17 for the next financial year.
Find out moreWhat is the trend in the Travere Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Travere Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +26.5%.
As of the last closing price of $30.44, shares in Travere Therapeutics were trading +14.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Travere Therapeutics PE Ratio?
The Travere Therapeutics PE ratio based on its reported earnings over the past 12 months is 48.9. The shares last closed at $30.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Travere Therapeutics?
Travere Therapeutics' management team is headed by:
- Gary Lyons - CHM
- Eric Dube - PRE
- Laura Clague - CFO
- Elizabeth Reed - SVP
- William Rote - SVP
- Sandra Calvin - CAO
- Peter Heerma - OTH
- Jula Inrig - OTH
- Stephen Aselage - DRC
- Roy Baynes - IND
- Suzanne Bruhn - IND
- Timothy Coughlin - IND
- Jeffrey Meckler - IND
- John Orwin - IND
- Sandra Poole - IND
- Ron Squarer - IND
- Ruth Williams-brinkley - IND